Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718 – Benzinga
|
Verastem Acquires Rights to Cancer Stem Cell Inhibitor VS-4718
Benzinga Verastem (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced that it has acquired the license to VS-4718 held originally by Poniard Pharmaceuticals. The previous and … |
